全文获取类型
收费全文 | 157篇 |
免费 | 6篇 |
专业分类
基础医学 | 13篇 |
临床医学 | 11篇 |
内科学 | 42篇 |
皮肤病学 | 3篇 |
特种医学 | 9篇 |
外科学 | 6篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
药学 | 9篇 |
肿瘤学 | 67篇 |
出版年
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 7篇 |
2014年 | 1篇 |
2013年 | 3篇 |
2012年 | 13篇 |
2011年 | 4篇 |
2010年 | 4篇 |
2009年 | 2篇 |
2008年 | 6篇 |
2007年 | 6篇 |
2006年 | 3篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 7篇 |
2001年 | 7篇 |
2000年 | 7篇 |
1999年 | 4篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1990年 | 4篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1947年 | 1篇 |
1934年 | 1篇 |
1920年 | 1篇 |
排序方式: 共有163条查询结果,搜索用时 71 毫秒
1.
van Besien K Bartholomew A Stock W Peace D Devine S Sher D Sosman J Chen YH Koshy M Hoffman R 《Bone marrow transplantation》2000,26(4):445-449
Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versus-host disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease. 相似文献
2.
Kim Margolin Michael B Atkins Janice P Dutcher Marc S Ernstoff John W Smith Joseph I Clark Joseph Baar Jeffrey Sosman Jeffrey Weber Chetan Lathia Janice Brunetti Frank Cihon Brian Schwartz 《Clinical cancer research》2007,13(11):3312-3319
PURPOSE: BAY 50-4798 is an analogue of interleukin-2 that selectively activates T cells over natural killer cells. This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics. EXPERIMENTAL DESIGN: Forty-five patients with metastatic melanoma or renal cancer were enrolled, 31 on escalating doses to determine the MTD, with 20 renal cell carcinoma patients treated at MTD to detect antitumor activity. BAY 50-4798 was delivered i.v. every 8 h, days 1 to 5 and 15 to 19, and could be repeated after 9 weeks if tumor was stable or responding. RESULTS: The MTD was defined by and reported in terms of doses received. The doses tested ranged from 1.3 to 26.1 microg/kg, and the MTD was defined as 10.4 microg/kg based on toxicities similar to those of aldesleukin. Two patients achieved partial responses, one with melanoma and one with renal cell carcinoma. Among all 45 patients, 53% and 9% experienced a grade 3 and 4 toxicity, respectively. Among the patients treated at the MTD of 10.4 microg/kg, 71% and 10% experienced a grade 3 and 4 toxicity, respectively. Pharmacokinetics showed dose-dependent peak concentrations (C(max)) and area under the curve with a half-life of approximately 2 h and no evidence of accumulation. Lymphocyte subset analysis confirmed the preferential expansion of T-cell subsets over natural killer cells. CONCLUSIONS: The antitumor activity of BAY 50-4798 in malignancies that respond to high-dose interleukin-2 was low. BAY 50-4798 might provide advantages over aldesleukin in antigen-specific immunotherapies. 相似文献
3.
Positron emission tomography with fluorine-18-deoxyglucose (FDG-PET) detects active lymphoid tissues during HIV-1 infection in man. We used FDG-PET to study anatomical correlates of HIV-1 infection in man. Whole-body FDG-PET images from 15 patients with HIV-1 showed distinct lymphoid tissue activation in the head and neck during acute disease, a generalised pattern of peripheral lymph-node activation at mid-stages, and involvement of abdominal lymph nodes during late disease. Unexpectedly, HIV-1 progression was evident by distinct anatomical correlates, suggesting that lymphoid tissues are engaged in a predictable sequence. Understanding the anatomy of HIV-1 infection could encourage use of surgical or radiological interventions to supplement chemotherapy. 相似文献
4.
Kirkwood JM Richards T Zarour HM Sosman J Ernstoff M Whiteside TL Ibrahim J Blum R Wieand S Mascari R 《Cancer》2002,95(5):1101-1112
BACKGROUND: The clinical antitumor activity of recombinant interferon alpha2b (IFNalpha2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. Trial E2690 evaluated the immunomodulatory effects of IFNalpha2b in vivo during treatment at high doses (the HDI arm; n = 51 patients) and at low doses (the LDI arm; n = 54 patients) in relation to standard observation (OBS; n = 43 patients). METHODS: This study evaluated peripheral blood lymphocytes (PBLs) for phenotypic markers and cytotoxic functions at 1 month, 3 months, and 12 months in the HDI arm, the LDI arm, and the OBS arm and examined correlations between changes observed in PBLs or in tumors with regard to treatment dosage and disease outcome. Tumor biopsy samples were studied for response to IFNalpha2b at a range of concentrations in vitro. RESULTS: Baseline blood phenotypic and functional assays did not predict disease outcome; however, modulation of these immunologic assays by IFNalpha2b treatment was observed and was associated with IFNalpha2b dosage. Tumor cell class II major histocompatibility antigen expression (human leukocyte/lymphocyte antigen DR) and adhesion molecule expression (ICAM-1) were modulated by exposure to IFNalpha2b in a dose dependent manner. Blood natural killer (NK) cell function, T-cell function, and subset distribution were modulated early by patients in the HDI arm and later by patients in the LDI arm. None of the variables tested in these studies predicted recurrence free survival. The numbers of patients studied were smaller than may be needed to detect potentially clinically significant changes. CONCLUSIONS: These data demonstrate changes in immunologic parameters associated with IFNalpha2b treatment and dosage that may account for some of the differences in the clinical efficacy of this modality. The current results also suggest the need for further study of newer molecular intermediates of IFNalpha2b and T-cell response to specific antigens of melanoma. 相似文献
5.
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer 总被引:6,自引:0,他引:6
P M Sondel P C Kohler J A Hank K H Moore N S Rosenthal J A Sosman R Bechhofer B Storer 《Cancer research》1988,48(9):2561-2567
Eleven patients received four consecutive weekly cycles of human recombinant interleukin 2 (IL-2) by continuous infusion for 4 days/week. Two dose levels were tested, 1 and 3 X 10(6) units/m2/day. Toxicities experienced by most patients included fever, rigors, fatigue, anemia, eosinophilia, and liver function abnormalities. All side effects from treatment reversed and no severe or life-threatening problems occurred. A marked lymphocytosis was seen following the 4 weeks of therapy. Fresh lymphocytes obtained during this lymphocytosis mediated enhanced destruction in vitro of a natural killer cell-resistant tumor cell line (Daudi). The increase in the absolute number of circulating lymphocytes and their enhanced ability to mediate direct lysis of Daudi targets resulted in a greater than 100-fold mean increase in cytotoxic potential by the end of IL-2 treatment. One patient, with renal carcinoma, who was treated at 3 X 10(6) units/m2/day experienced a sustained measurable response with greater than 50% regression of pulmonary and hepatic metastases. Five patients were retreated with a second course of IL-2, lasting 4 weeks. This therapy was well tolerated in four of these five patients, with similar immunological changes occurring. No further antitumor responses were seen in these patients. Thus, a relatively well tolerated immunotherapy regimen using IL-2 can induce dramatic increases in lymphocyte number and augment their in vitro antitumor reactivity. 相似文献
6.
7.
Lipohemarthrosis of the knee: a review of recent experiences 总被引:4,自引:0,他引:4
The radiographs of 268 patients with knee trauma were retrospectively reviewed. In 15 patients with intraarticular fracture, the images demonstrated fat-fluid levels. In 28 other patients with intraarticular fracture, only joint effusion without a fat-fluid level was depicted. The presence of a fat-fluid level in the knee indicated fracture in all patients in whom it was seen. The absence of such a level, however, did not exclude intraarticular fracture. 相似文献
8.
Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit.
These poor results come from treating melanoma as a single homogeneous disease. Recently, it has been shown that targeting
activated tyrosine kinases (oncogenes) can mediate striking clinical benefits in several cancers. In 2002, a mutation at the
V600E amino acid of the BRAF serine/threonine kinase was described as present in over 50% of melanomas. The mutation appeared
to confer a dependency by the melanoma cancer cell on its activation of the MAP kinase pathway. The frequency and specificity
of this mutation (95% at V600E of BRAF) suggests that it may be a potential target for therapy, and recent results with one
inhibitor, PLX4032/RG7204, bare this out. This review updates the status of BRAF inhibitors in melanoma and what may be on
the horizon. 相似文献
9.
Bernard Escudier Padmanee Sharma David F. McDermott Saby George Hans J. Hammers Sandhya Srinivas Scott S. Tykodi Jeffrey A. Sosman Giuseppe Procopio Elizabeth R. Plimack Daniel Castellano Howard Gurney Frede Donskov Katriina Peltola John Wagstaff Thomas C. Gauler Takeshi Ueda Huanyu Zhao Robert J. Motzer 《European urology》2018,73(4):e116-e118
10.